An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Sponsor
Genentech, Inc.
Study ID
NCT00109057
Phase
PHASE2
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not show evidence of disease progression at completion of the parent study will be eligible for inclusion in this trial.

Key Dates

First listed
Apr 25, 2005
Start date
Feb 28, 1998
Status verified
Jun 2013
Completion
Feb 29, 2004

Study Design

Enrollment
56 participants (actual)
Primary purpose
TREATMENT

Related Studies